Actio Biosciences is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and autoimmune diseases. The company leverages its proprietary drug discovery platform to target the LXR (Liver X Receptor) and ROR (Retinoic Acid Receptor-Related Orphan Receptor) pathways, which are involved in regulating immune responses and are implicated in various diseases.

Actio Biosciences

We’re leveraging advances in genetics and precision medicine to develop new therapeutics that target shared, underlying biology in rare and common diseases — bringing meaningful medicines from one to many. 

With expertise in genetics, drug discovery and data sciences, we seek to identify programs where both biological and technical risk can be minimized to streamline the drug development process and bring forward exceptionally potent and precisely targeted therapeutics for patients. 

Actio Biosciences, Inc.

Will we see you at #BiocomGPIC? Actio CEO and Co-Founder, David B. Goldstein, Ph.D. will take the presenter’s stage on Wednesday, February 28th at 3:45 p.m. PST to talk about Actio and our pursuit to develop life-changing treatments that target underlying shared biology between rare and common diseases. 

At Actio, our people are our driving force. With unique experiences and an overwhelming drive to identify therapies for rare diseases, each member of our team exemplifies our commitment to our core values - including a dedication to scientific rigor. 
 
Meet our associate director, Shelby Gough, an extraordinary leader, who works with her team to de-risk biology and identify high-value targets of interest that can be translated into medicines that make an impact on patients in need. Learn more about Shelby's work and how she and her team strive for scientific rigor every day. 

It’s a pleasure to welcome Samuel Collins, MBBS, Ph.D., MBA as our chief medical officer. As a trained pediatric physician, Dr. Collins joins us with more than 20 years of experience in academia and industry, with a focus in rare diseases and pediatrics. 

Dr. Collins will be pivotal in overseeing all aspects of our clinical development and medical and regulatory affairs for our pipeline of precision medicines. We’re thrilled to add his expertise to our team as we work to bring meaningful medicines from one to many. 

Read more from the announcement below.

COM:ACTIOBIOSCIENCES

Actio Biosciences